Trial intelligence / Profile preview

MSC and SVF Injection for Knee Osteoarthritis

NCT03164083Phase 2Withdrawn

Sponsor
SCARM Institute
Start
Nov 2019
Primary completion
Aug 2020
Modality
Stem Cell Therapies
Countries
1
01

Overview

A Phase 2 trial of mesenchymal stem cells, autologous adipose stromal vascular fraction in osteoarthritis (OA), sponsored by SCARM Institute. Planned start Nov 2019; status: withdrawn.

02

Drugs

mesenchymal stem cellsautologous adipose stromal vascular fraction
03

Conditions

osteoarthritis (OA)

Beyond the preview

Go deeper on NCT03164083.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT03164083.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call